ZFIN ID: ZDB-FISH-180326-2
Fish name: sh144Tg/sh144Tg
Genotype: sh144Tg/sh144Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by sh144Tg/sh144Tg
No data available
GENE EXPRESSION
Gene expression in sh144Tg/sh144Tg
RNA expression
Expressed Gene Structure Conditions Figures
fkbp5 control Fig. 1 with image from Vettori et al., 2017
chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
hpxa control Fig. 1 with image from Vettori et al., 2017
chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
p4ha1b control Fig. 1 with image from Vettori et al., 2017
chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
pck1 control Fig. 1 with image from Vettori et al., 2017
chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
pfkfb3 control Fig. 1 with image from Vettori et al., 2017
chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
scarb1 control Fig. 1 with image from Vettori et al., 2017
chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
tsc22d3 control Fig. 1 with image from Vettori et al., 2017
chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
Protein expression No data available
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP control Fig. 1 with image from Vettori et al., 2017
chemical treatment: betamethasone, chemical treatment: mifepristone Fig. 1 with image from Vettori et al., 2017
PHENOTYPE
Phenotype in sh144Tg/sh144Tg
Phenotype Conditions Figures
liver EGFP expression amount, ameliorated chemical treatment: betamethasone, chemical treatment: mifepristone Fig. 1 with image from Vettori et al., 2017
liver EGFP expression increased amount, abnormal chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
whole organism pck1 expression increased amount, abnormal chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: 8-methoxy-2-(2-methoxyphenyl)-1-benzopyran-4-one Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: 5-hydroxy-2,8-dimethyl-6,9-dihydropyrano[3,2-h][1]benzoxepin-4-one Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: 7-NITROINDAZOLE Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: cortisol 17-butyrate Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: Triamcinolone diacetate Fig. 1 with image from Vettori et al., 2017
whole organism hpxa expression increased amount, abnormal chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: dimethyloxalylglycine, chemical treatment: mifepristone Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: triamcinolone acetonide Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
whole organism fkbp5 expression increased amount, abnormal chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: dimethyloxalylglycine Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: dexamethasone Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: ciclopirox olamine Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: icariin Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: Fluocinonide Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: Halcinonide Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: amcinonide Fig. 1 with image from Vettori et al., 2017
whole organism EGFP expression increased amount, abnormal chemical treatment: clobetasol propionate Fig. 1 with image from Vettori et al., 2017
whole organism p4ha1b expression increased amount, abnormal chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
whole organism tsc22d3 expression increased amount, abnormal chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
whole organism scarb1 expression increased amount, abnormal chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017
whole organism pfkfb3 expression increased amount, abnormal chemical treatment: betamethasone Fig. 1 with image from Vettori et al., 2017

CITATIONS  (1)